You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD

    SBC: ONL Therapeutics, Inc.            Topic: NEI

    PROJECT SUMMARYABSTRACT Age related macular degenerationAMDis the leadingand due to the aging baby boomersa growing cause of irreversible vision loss in the United Statesand is strongly associated with exposure to cigarette smokeCSand high fat dietsHFDWhile effective treatment is available for neovascular AMDthe AREDS II antioxidant vitamins are the only proven treatment for intermediate dry AMDUn ...

    STTR Phase I 2018 Department of Health and Human Services
  2. A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn

    SBC: MicroCures Inc.            Topic: NEI

    The cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humansCorneal tissue injuries are the most common everyday issue for practicing ophthalmologists and can run the gamut in severityIn severe modelssuch as corneal alkaline burnsextensive healing is needed and often the burn victim is left with reduced visual acuityHealing of large ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial

    SBC: Elm Tree Medical Inc.            Topic: NICHD

    Measurement of cervical dilation during late pregnancy and labor informs decisions in the management of labor and deliveryPrior published research suggests that practitioners are onlytoaccurate when judging cervical simulatorsWhen measuring laboring womentwo practitionersandaposmeasurements agree onlyof the timeDrEva Martin of Elm Tree Medical Incdeveloped a novel deviceDilaCheckto enable practiti ...

    STTR Phase I 2018 Department of Health and Human Services
  5. A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy

    SBC: MicroCures Inc.            Topic: 300

    Radical prostatectomyRPis a commonly used treatment option for localized prostate cancerUnfortunatelythe procedure carries a risk of post surgical complications including a high risk of erectile dysfunctionEDAccording to The Prostate Cancer Outcomes Studyvirtually all men experience ED after surgeryincluding a profound loss of nocturnal erectionsThe Prostate Cancer Outcomes Study further reveals t ...

    STTR Phase I 2018 Department of Health and Human Services
  6. Protein ProFiler Microfluidic Electrophoresis System for Proteomics

    SBC: InnovaRegi LLC            Topic: 400

    AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...

    STTR Phase I 2018 Department of Health and Human Services
  7. Optimizing Direct Delivery of Nucleic Acid Therapeutics

    SBC: FHC, INC.            Topic: NIMH

    Project Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GlyTR Therapeutics, Inc.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Point of care detection of extracellular vesicles in urine for diagnosis of preeclampsia

    SBC: Sersense Inc            Topic: NICHD

    PreeclampsiaPEis a pregnancy specific disorder characterized by hypertension and commonly by the appearance of urinary proteinThis disorder occurs inof pregnancies worldwide and is the second leading cause of maternal fetal morbidity and mortality worldwideIn low resource settingsPE accounts for up toof maternal deathsThe etiology of this disease is poorly understoodThis confounds therapeutic inte ...

    STTR Phase I 2018 Department of Health and Human Services
  10. Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin)

    SBC: Serplus Technology, LLC            Topic: 200

    The number of people with diabetes worldwide is predicted to increase frommillion intomillion inThe health care costs of treating the disease account forof the global health expenditure and continue to be a huge economic burdenIDF World AtlasTypediabetes mellitusT DMconstitutesof the disease burdenIt is an autoimmune diseasethought to be triggered by genetic or environmental factors in early child ...

    STTR Phase I 2018 Department of Health and Human Services
US Flag An Official Website of the United States Government